Patents by Inventor Giangiacomo Torri

Giangiacomo Torri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20010044424
    Abstract: The present invention provides a peritoneal dialysis solution that contains heat stable osmotic agents such as D-glucitols, gluconic acids and alkylglycosides produced the reduction, oxidation or glycosylation of icodextrins respectively. As a result, osmotic agents that are stable under autoclaving or heat sterilization conditions are provided which reduces the amount of bioincompatible materials in the sterilized peritoneal dialysis solutions. Methods of preparing the D-glucitols, gluconic acids and alkylglycosides are disclosed.
    Type: Application
    Filed: June 15, 2001
    Publication date: November 22, 2001
    Inventors: Annamaria Naggi, Enrico Petrella, Giangiacomo Torri, Benito Casu
  • Patent number: 6197943
    Abstract: Glycosaminoglycans having high antithrombotic activity in vitro, obtained by various kinds of glycosaminoglycans supersulfated by the preparation of the salt of an organic base of the starting supersaturated glycosaminoglycan, by partial solvolytic desulfation of said salt and N-resulfation of said partially desulfated product.
    Type: Grant
    Filed: September 20, 1999
    Date of Patent: March 6, 2001
    Assignee: Inalco S.p.A.
    Inventors: Benito Casu, Annamaria Naggi, Giangiacomo Torri
  • Patent number: 5780616
    Abstract: The invention relates to a cationic polysaccharide, preferably in fibrous form, having superabsorbent characteristics. The polysaccharides are substituted by quaternary ammonium groups, have a ds of at least 0.5, preferably 0.5 to 2.5 and are cross-linked to a sufficient extent that it remains insufficient in water. The polysaccharide is preferably cellulose. An increased number of functional groups in the product improves superabsorbent properties, whereas use of a cross-linking agent makes it possible to control the gel strength of the product and makes it easier to tailor the characteristics of the product to those which are required.
    Type: Grant
    Filed: July 10, 1997
    Date of Patent: July 14, 1998
    Assignee: The Procter & Gamble Company
    Inventors: Giancarlo Fornasari, Giangiacomo Torri, Giovanni Carlucci
  • Patent number: 5152998
    Abstract: By ultrafiltration of an aqueous solution wherein there have been formerly dissolved alfa-cyclodextrin and a raw lipidic mixture, the latter characterized in that it contains monosialoganglioside (GMl) either as the sole ganglioside or otherwise in a prevailing quantity over the other associated gangliosides, and after the removal of cyclodextrin at the end of the process, it is obtained GMl with a titer of at least 95%. The present invention concerns also the intermediate complex that it is being formed between the hereabove said monosialoganglioside and alfa-cyclodextrin.
    Type: Grant
    Filed: February 12, 1992
    Date of Patent: October 6, 1992
    Assignee: Crinos Industria Farmacobiologica SpA
    Inventors: Benito Casu, Ennio Lanzarotti, Giangiacomo Torri, Annamaria Naggi, Armando Cedro
  • Patent number: 5110918
    Abstract: Heparins, heparin fractions or fragments, optionally salified with pharmaceutically acceptable cations, having molecular weight ranging from 1.000 to 30.000 D, characterized by an EDTA content lower than 0.1%, by the absence, in the .sup.1 H--NMR spectra, of the signals due to EDTA between 2.50 and 4.00 p.p.m. and substantially free from bleeding effect and optionally free from signals, in the .sup.13 C--NMR spectrum, from 80 to 86 ppm.
    Type: Grant
    Filed: September 24, 1990
    Date of Patent: May 5, 1992
    Assignee: Sanofi S.A.
    Inventors: Benito Casu, Annamaria Naggi, Pasqua Oreste, Giangiacomo Torri, Giorgio Zoppetti, Giancarlo Sportoletti, Francesco De Santis
  • Patent number: 5108613
    Abstract: By ultrafiltration of an aqueous solution wherein there have been formerly dissolved alfa-cyclodextrin and a raw lipidic mixture, the latter characterized in that it contains monosialoganglioside (GM1) either as the sole ganglioside or otherwise in a prevailing quantity over the other associated gangliosides, and after the removal of cyclodextrin at the end of the process, it is obtained GM1 with a titer of at least 95%. The present invention concerns also the intermediate complex that it is being formed between the hereabove said monosialoganglioside and alfa-cyclodextrin.
    Type: Grant
    Filed: July 15, 1991
    Date of Patent: April 28, 1992
    Assignee: Crinos Industria Farmacobiologica S.p.A.
    Inventors: Benito Casu, Ennio Lanzarotti, Giangiacomo Torri, Annamaria Naggi, Armando Cedro
  • Patent number: 5010064
    Abstract: Inclusion complexes of dipyridamole with beta cyclodextrins in the molar ratio of dipyridamole to cyclodextrin ranging from 1:1 to 1:12 provides higher and more consistent blood concentrations than can be achieved by the dipyridamole alone.
    Type: Grant
    Filed: June 1, 1988
    Date of Patent: April 23, 1991
    Assignee: Edmond Pharma s.r.l.
    Inventors: Giancarlo Fregnan, Guido Vandoni, Giangiacomo Torri
  • Patent number: 5008253
    Abstract: Novel derivatives are disclosed as obtained from chondroitin sulfate, dermatan sulfate and hyaluronic acid, having a molar ratio between sulfate groups and carboxylic groups like that of heparin and furthermore characterized by possessing, as the heparin, the sulfoamino group at the carbon atom at the 6 position of hexosamine.The novel compounds show a very remarkable clearing activity in comparison with the starting mucopolysaccharides, this activity being similar and for some derivatives comparable with that of heparin.Moreover, differently from what normally happens upon sulfating the sulfomucopolysaccharides, the anticoagulating activity of the novel compounds is negligible or anyhow very reduced.The compounds of the present invention find use in the therapy of arteriosclerosis.
    Type: Grant
    Filed: May 2, 1989
    Date of Patent: April 16, 1991
    Assignee: Crinos Industria Farmacobiologica S.p.A.
    Inventors: Benito Casu, Giangiacomo Torri, Annamaria Naggi, Marisa Mantovani, Rodolfo Pescador, Roberto Porta, Giuseppe Prino
  • Patent number: 4948881
    Abstract: Process for the depolymerization and sulfation of polysaccharides by reaction of said polysaccharides with a sulfuric acid/chlorosulfonic acid mixture.
    Type: Grant
    Filed: January 27, 1989
    Date of Patent: August 14, 1990
    Assignee: Sanofi
    Inventors: Annamaria Naggi, Giangiacomo Torri
  • Patent number: 4727063
    Abstract: Novel depolymerized and supersulfated heparin having a molecular weight comprised between 2000 and 9000 and a sulfation degree of at least 2.5, in which all of the primary hydroxy groups are sulfated; a process for its preparation by reacting a heparin of natural origin, or a fraction thereof with a sulfuric acid/chlorosulfonic acid mixture; and pharmaceutical compositions containing it as active ingredient, having potential antithrombotic, hypolipemic and fibrinolytic activity and useful in the prevention of thrombosis and for the treatment of atherosclerosis.
    Type: Grant
    Filed: May 24, 1985
    Date of Patent: February 23, 1988
    Assignee: Sclavo
    Inventors: Annamaria Naggi, Giangiacomo Torri
  • Patent number: 4432801
    Abstract: A process for the controlled degradation of liquid glucose syrups in concentrated solution and in homogeneous phase wherein the reducing groups of glucose, maltose and maltodextrin are converted into the salts of the corresponding aldonic acids and/or into the salts of lower carboxylic acids (C.sub.1 -C.sub.4) without substantially changing the polysaccharide components (degree of polymerization>3) of maltodextrin, or with only partial depolymerization of the polysaccharide components, by using simple oxidants such as hypohalogenites or ferricyanides, or aqueous alkaline solutions. The conversion of the reducing sugars is equal to or greater than 95%, and a very high reproductibility of the desired results is obtained. The invention also concerns the product obtained by the process and its use as an additive to cement mortars and concretes.
    Type: Grant
    Filed: May 4, 1981
    Date of Patent: February 21, 1984
    Assignee: Grace Italiana S.p.A.
    Inventors: Fabio Tegiacchi, Mario Chiruzzi, Benito Casu, Giangiacomo Torri
  • Patent number: 4411796
    Abstract: A novel polyaminic resin obtained by crosslinking a polyalkyleneamine (in particular polyethyleneamine) with diisocyanates in solution, is useful as a selective separation or extraction agent of a component having a "complementary" chemical structure (particularly heparin), by means of mere contact or "ionic exchange" with aqueous solutions containing it. Heparin is thus even quantitatively extracted from solutions containing it alone or in mixture with other glucosaminoglycanes. The polyamine can then release the "adsorbed" heparin and be recovered by a treatment with saline solutions. The novel resin is used in pharmaco-biological fields.
    Type: Grant
    Filed: September 29, 1982
    Date of Patent: October 25, 1983
    Assignee: Crinos Industria Farmabiologica, S.p.A.
    Inventors: Benito Casu, Giangiacomo Torri, Giorgio Zoppetti
  • Patent number: 4369256
    Abstract: A novel polyaminic resin obtained by crosslinking a polyalkyleneamine (in particular polyethyleneamine) with diisocyanates in solution, is useful as a selective separation or extraction agent of a component having a "complementary" chemical structure (particularly heparin), by means of mere contact or "ionic exchange" with aqueous solutions containing it. Heparin is thus even quantitatively extracted from solutions containing it alone or in mixture with other glucosaminoglycanes. The polyamine can then release the "adsorbed" heparin and be recovered by a treatment with saline solutions. The novel resin is used in pharmaco-biological fields.
    Type: Grant
    Filed: April 6, 1981
    Date of Patent: January 18, 1983
    Assignee: Crinos Industria Farmacobiologica S.p.A.
    Inventors: Benito Casu, Giangiacomo Torri, Giorgio Zoppetti